FDA Review Looms As Replimune Faces Weak Technical Setup

Benzinga_recent_news04-09 23:19

Replimune Group (NASDAQ:REPL) shares are down on Thursday. The company faces an upcoming FDA review decision on Friday, 10 April. In October 2025, the U.S. Food and Drug Administration (FDA) accepted ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626136453?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/09/Silver-Spring--Md--Usa---June-25--2022-T.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-04-09 23:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626136453","market":"sh","top_or_hot":-1,"title":"FDA Review Looms As Replimune Faces Weak Technical Setup","media":"Benzinga_recent_news","content":"<div>\n<p>Replimune Group (NASDAQ:REPL) shares are down on Thursday.\nThe company faces an upcoming FDA review decision on Friday, 10 April.\nIn October 2025, the U.S. Food and Drug Administration (FDA) accepted ...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/26/04/51734545/fda-review-looms-as-replimune-faces-weak-technical-setup\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Review Looms As Replimune Faces Weak Technical Setup</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Review Looms As Replimune Faces Weak Technical Setup\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-09 23:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/fda/26/04/51734545/fda-review-looms-as-replimune-faces-weak-technical-setup><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Replimune Group (NASDAQ:REPL) shares are down on Thursday.\nThe company faces an upcoming FDA review decision on Friday, 10 April.\nIn October 2025, the U.S. Food and Drug Administration (FDA) accepted ...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/26/04/51734545/fda-review-looms-as-replimune-faces-weak-technical-setup\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"https://www.benzinga.com/news/fda/26/04/51734545/fda-review-looms-as-replimune-faces-weak-technical-setup","article_id":"2626136453","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/09/Silver-Spring--Md--Usa---June-25--2022-T.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/04/51734545/fda-review-looms-as-replimune-faces-weak-technical-setup","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2626136453","pubTimestamp":1775747940,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Replimune awaits FDA decision on RP1 for skin cancer after initial rejection, with weak technicals and prior rejection concerns.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LABU":"三倍做多标普生物-Direxion","BK4585":"ETF&股票定投概念","SMA":"Smartstop Self Storage REIT Inc","REPL":"Replimune Group Inc.","BK4139":"生物科技","BK4150":"赌场与赌博","BK4217":"自存仓储房地产信托","RSI":"Rush Street Interactive, Inc.","BK4588":"碎股"},"translate_title":"Replimune面临薄弱的技术设置，FDA审查迫在眉睫","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"SMA":1,"REPL":1,"RSI":1},"content_text":"Replimune Group (NASDAQ:REPL) shares are down on Thursday.\nThe company faces an upcoming FDA review decision on Friday, 10 April.\nIn October 2025, the U.S. Food and Drug Administration (FDA) accepted the resubmission of the Biologics License Application (BLA) for RP1 in combination with nivolumab for advanced melanoma patients who progress on an anti-PD-1 containing regimen.\nIn June 2025, the FDA issued a Complete Response Letter for the company's RP1 (vusolimogene oderparepvec).\nThe FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.\nAs per a media report in August 2025, the FDA's top cancer drug regulator stepped in during the final stages of a heated review of Replimune's skin cancer treatment — a move that played a key role in the drug being rejected at the last minute, despite support from some within the agency.\nOngoing leadership changes, staff turnover, and internal issues at the FDA influenced the review process and the decision to deny approval.\nReplimune found itself caught in the middle of the agency's internal turmoil.\nThe company said existing cash, cash equivalents, and short-term investments of $269.1 million will provide cash runway late into the first quarter of calendar 2027.\nAt $5.79, the stock is trading 20.7% below its 20-day simple moving average (SMA) and 30.2% below its 100-day SMA, suggesting significant short-term weakness. This positioning indicates that the stock is struggling to gain momentum in the near term.\nThe relative strength index (RSI) is currently at 35.33, which is neutral but leans toward bearish territory, indicating potential downward pressure.\nThe moving average convergence divergence (MACD) shows a bearish trend, with the MACD at -0.0632 and the signal line at -0.0458, suggesting that selling pressure may persist.\nReplimune's 12-month performance shows a decline of 19.49%, reflecting a challenging year for the stock.\nCurrently, it is trading near the middle of its 52-week range, which indicates a lack of strong directional momentum.\nBelow is the Benzinga Edge scorecard for Replimune Group, highlighting its strengths and weaknesses compared to the broader market:\nREPL Price Action: Replimune Group shares were down 3.99% at $5.65 at the time of publication on Thursday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626136453","isCrawlerRequest":true}